Prime Medicine, Inc. 8-K

What Happened
Prime Medicine, Inc. (PRME) filed a Form 8-K on January 12, 2026 to disclose under Regulation FD that it posted an updated corporate presentation to its investor website (https://investors.primemedicine.com/news-events). A copy of that presentation is furnished as Exhibit 99.1 to the 8-K. The report was signed by Allan Reine, M.D., Chief Executive Officer.

Key Details

• Date filed: January 12, 2026 (Form 8-K, Regulation FD disclosure).
• Presentation furnished as Exhibit 99.1 to the 8-K.
• Investor website referenced: https://investors.primemedicine.com/news-events (company states the website reference is inactive textual reference only and not incorporated by reference).
• Report signed by Allan Reine, M.D., Chief Executive Officer.

Why It Matters
This filing informs investors that Prime Medicine has made updated corporate materials available publicly and has furnished that presentation to the SEC, ensuring broad, non‑selective disclosure under Regulation FD. The 8-K does not announce financial results, an executive change, or a corporate transaction — it simply documents the posting and SEC furnishing of the presentation. Investors who want current corporate or program information should review the furnished presentation directly (Exhibit 99.1).